Abstract From 1979 through July 1983, 859 patients were enrolled in a Phase III RTOG
Protocol (7916) evaluating the role of Misonidazole combined with radiation in the treatment …

The overall poor prognosis of brain metastases patients has complicated the evaluation of
treatment effectiveness in previous clinical trials involving radiation therapy. Therapy has not …

The search continues for a favorable subgroup of patients with brain metastases in whom
testing of new modalities might show a benefit in overall survival. Complete pre-and post …

One hundred sixteen eligible patients with metastatic cancer to the brain were randomized
to receive either radiotherapy 3000 rad/10 fractions (treatment 1) or the same radiotherapy …

This paper presents a review of the progressive clinical trials of the hypoxic cell
radiosensitizer, misonidazole, in the Radiation Therapy Oncology Group (RTOG) …

Purpose/Objective: Based on our previous phase II study, where radiographic response was
significantly higher in the group receiving temozolomide (TMZ) with whole brain …

PURPOSE: To determine the efficacy, tolerability, and safety of concurrent temozolomide
and radiotherapy in patients with previously untreated brain metastases. PATIENTS AND …

Purpose: To determine if the addition of bromodeoxyuridine (BrdUrd) to radiotherapy
prolongs survival when compared to radiotherapy alone in patients with brain metastases …

Abstract Between May 1980 and July 1983, the RTOG conducted a randomized prospective
study comparing external radiation therapy and misonidazole to radiation therapy alone for …

PURPOSE: To evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT)
concomitantly with temozolomide (TMZ) in patients with brain metastases (BM). METHODS …